Evidence map›Paper›PMID 41226691›Full record

ArticleInternational journal of molecular sciences2025

Gα

Veronika Leiss, Katja Pexa, Andreas Nowacki, James P Bridges, Benedikt Duckworth-Mothes, Susanne Ammon-Treiber, Ana Novakovic, Franziska Zeyer, Hartwig Wolburg, Petra Fallier-Becker and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Veronika LeissDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute of Experimental and Clinical Pharmacology and Pharmacogenomic, Interfaculty Center for Pharmacogenomics and Drug Research, Eberhard Karls University Tübingen and University Clinic, 72076 Tübingen, Germany.
Katja PexaInstitute for Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Andreas NowackiDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute of Experimental and Clinical Pharmacology and Pharmacogenomic, Interfaculty Center for Pharmacogenomics and Drug Research, Eberhard Karls University Tübingen and University Clinic, 72076 Tübingen, Germany.
James P BridgesDepartment of Medicine, National Jewish Health, Denver, CO 80222, USA.ORCID 0000-0002-4815-117X
Benedikt Duckworth-MothesDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute of Experimental and Clinical Pharmacology and Pharmacogenomic, Interfaculty Center for Pharmacogenomics and Drug Research, Eberhard Karls University Tübingen and University Clinic, 72076 Tübingen, Germany.ORCID 0000-0002-2352-2325
Susanne Ammon-TreiberDepartment of Pharmacology, Toxicology and Clinical Pharmacy, Institute for Pharmacy, University of Tübingen, 72076 Tübingen, Germany.
Ana NovakovicDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute of Experimental and Clinical Pharmacology and Pharmacogenomic, Interfaculty Center for Pharmacogenomics and Drug Research, Eberhard Karls University Tübingen and University Clinic, 72076 Tübingen, Germany.
Franziska ZeyerInterdisciplinary Paediatric Intensive Care Unit 34, Clinic for Paediatrics and Adolescent Medicine, University Clinic Tübingen, 72016 Tübingen, Germany.ORCID 0009-0003-4692-4575
Hartwig WolburgInstitute of Pathology and Neuropathology, Comprehensive Cancer Center, Eberhard Karls University Tübingen and University Clinic, 72074 Tübingen, Germany.
Petra Fallier-BeckerInstitute of Pathology and Neuropathology, Comprehensive Cancer Center, Eberhard Karls University Tübingen and University Clinic, 72074 Tübingen, Germany.
Roland P PiekorzInstitute for Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Matthias SchwabDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.ORCID 0000-0002-9984-075X
Letizia Quintanilla-MartínezInstitute of Pathology and Neuropathology, Comprehensive Cancer Center, Eberhard Karls University Tübingen and University Clinic, 72074 Tübingen, Germany.ORCID 0000-0001-7156-5365
Sandra Beer-HammerDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute of Experimental and Clinical Pharmacology and Pharmacogenomic, Interfaculty Center for Pharmacogenomics and Drug Research, Eberhard Karls University Tübingen and University Clinic, 72076 Tübingen, Germany.ORCID 0000-0001-6049-0257
Bernd NürnbergDepartment of Pharmacology, Experimental Therapy and Toxicology, Institute of Experimental and Clinical Pharmacology and Pharmacogenomic, Interfaculty Center for Pharmacogenomics and Drug Research, Eberhard Karls University Tübingen and University Clinic, 72076 Tübingen, Germany.ORCID 0000-0002-5995-6555

Funding

Deutsche Forschungsgemeinschaft SFB 612, GRK 1089, and Nu53/13-1
6 · The paper itself

Abstract

Heterotrimeric G

Indexed as

Adaptation, PhysiologicalGTP-Binding Protein alpha Subunit, Gi2Respiratory Distress Syndrome, NewbornSignal TransductionAnimalsAnimals, NewbornFemaleMaleMiceMice, KnockoutPulmonary AlveoliPulmonary SurfactantsGnai2 protein, mouseGTP-Binding Protein alpha Subunit, Gi2Pulmonary SurfactantsGαi2Gαi-signalinglung developmentneonatal lethalityrespiratory distress syndrome (RDS)surfactant

Identifiers

PMID41226691
PMCPMC12610543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.